



Komal Dangi Joins AptaPharma as Managing Partner, Ushering in a New Era of Innovation and Strategic Growth

Komal Dangi Joins AptaPharma as Managing Partner, Ushering in a New Era of Innovation and Strategic Growth

PENNSAUKEN NJ, NJ, UNITED STATES, September 5, 2025 /EINPresswire.com/ -- AptaPharma Inc., a rising force in the pharmaceutical industry recognized for its innovative formulation technologies and patient-focused solutions, proudly announces the appointment of Komal Dangi as its new Managing Partner. This strategic leadership addition signals a bold new chapter for AptaPharma, as the company prepares to accelerate innovation, expand global partnerships, and deepen its impact across the pharmaceutical landscape.

Komal Dangi brings over 15 years of executive leadership and entrepreneurial success to AptaPharma, backed by a proven track record across technology, HR, and pharmaceutical sectors. As the founder and CEO of Synkriom Inc. and VeriKlick, she has driven transformative growth for a wide range of organizations—including pharmaceutical companies and Contract Development and Manufacturing Organizations (CDMOs). Her expertise in strategic planning, recruitment, and digital transformation, combined with a deep understanding of regulatory environments, clinical workflows, and supply chain dynamics, has made her a trusted partner to some of the industry's most respected names.

"I'm thrilled to join AptaPharma at such a pivotal moment," said Dangi. "The company's commitment to advancing science and improving patient outcomes aligns perfectly with my passion for innovation and impact. With my background in pharma consulting and digital strategy, I see tremendous opportunity to scale Apta's reach and redefine what's possible in drug delivery and development.

AptaPharma, headquartered in Pennsauken, NJ, is rapidly emerging as a leader in novel formulation development, advanced drug delivery platforms, and high-quality oral liquid and solid dosage products. With a robust pipeline and an innovation-driven approach, the company is poised to disrupt traditional models and deliver therapies that are more effective, accessible, and sustainable.

Dangi joins forces with Ishwar Chauhan, President and Co-Founder, and Dr. Siva Rama Krishna Nutalapati, Executive Vice President of Technology Development and Co-Founder. Together, this

powerhouse leadership team is gearing up for a series of strategic launches, expanded R&D initiatives, and new global collaborations designed to elevate AptaPharma's position in the industry.

About AptaPharma Inc.

AptaPharma is dedicated to developing and manufacturing innovative drug formulations and advanced delivery platforms. By combining regulatory excellence, scientific rigor, and a patient-first mindset, Apta is redefining the future of accessible, high-quality medicines.

Monique Burgener

Synkriom Inc

[email us here](#)

Visit us on social media:

[LinkedIn](#)

[Facebook](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/846109743>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.